Ambrx Biopharma Inc. Financing Cash Flow
Ambrx Biopharma Inc. reported Financing Cash Flow of $159.87 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2023-08-09
- Ambrx Biopharma Inc. net cash provided by (used in) financing activities for the quarter ending 2023-06-30 was $82.65M.
- Ambrx Biopharma Inc. net cash provided by (used in) financing activities for the quarter ending 2023-03-31 was $77.22M.
- Ambrx Biopharma Inc. net cash provided by (used in) financing activities for the quarter ending 2022-06-30 was -$28.00K.
- Ambrx Biopharma Inc. net cash provided by (used in) financing activities for the quarter ending 2022-03-31 was -$6.00K.
- Ambrx Biopharma Inc. net cash provided by (used in) financing activities for fiscal 2022 was $928.00K, a 99.27% decline from fiscal 2021.
- Ambrx Biopharma Inc. net cash provided by (used in) financing activities for fiscal 2021 was $127.43M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|
| 2023-06-30 | $82.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $159.87M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $77.22M 10-Q · filed 2023-05-11 | ||
| 2022-12-31 | $928.00K 10-K · filed 2023-03-30 | ||
| 2022-06-30 | -$28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$34.00K 10-Q · filed 2023-08-09 | |
| 2022-03-31 | -$6.00K 10-Q · filed 2023-05-11 | ||
| 2021-12-31 | $127.43M 10-K · filed 2023-03-30 | ||
| 2021-06-30 | $95.49M 6-K · filed 2022-08-29 | ||
| 2020-12-31 | $95.68M 20-F · filed 2022-04-26 | ||
| 2019-12-31 | $0.00 20-F · filed 2022-04-26 |